EUVIMEDEUVIMED entdecken
Crossref

Statin and Immune-Related Cardiovascular Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Junmin Song, Kuan-Yu Chi, Hyein Jeon, Yu-Cheng Chang, Nutchapon Xanthavanij, Zhiting Tang, Yu Chang, Cho-Hung Chiang, Yu-Shiuan Lin, Shuwen Lin, Xiaocao Haze Xu, Cho-Han Chiang

Oncology · 21.05.2025 · 104 (3) · 319-326

DOI: 10.1159/000546204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 21.05.2025. Verfasst von Junmin Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lung Neoplasms, Immune Checkpoint Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with an increased risk of cardiotoxicity. We investigated whether statins could mitigate ICI-associated cardiovascular risks in lung cancer patients.

Methods

We performed a retrospective, propensity score-matched cohort study utilizing the TriNetX database. We identified lung cancer patients receiving ICIs between April 2013 and June 2023. We created two cohorts: statin users and non-users. The primary efficacy outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischemic stroke, and heart failure. The secondary efficacy outcomes were myocarditis and cardiac arrest. Safety outcomes were all-cause mortality and serious immune-related adverse events (irAEs).

Results

A total of 16,650 lung cancer patients undergoing ICIs were identified, consisting of 6,812 statin users and 9,838 non-users. After propensity score matching, 4,379 patients were well-matched in baseline characteristics. Over a follow-up period of 12 months, statin use was associated with a lower risk of MACE (HR: 0.87, 95% CI: 0.78–0.98), primarily driven by reductions in myocardial infarction (HR: 0.75, 95% CI: 0.58-0.97) and heart failure (HR: 0.85, 95% CI: 0.74–0.98). For safety outcomes, statin use was associated with a reduction in all-cause mortality (HR: 0.83, 95% CI: 0.77–0.90) and did not result in an increased risk of serious irAEs.

Conclusion

The use of statins in lung cancer patients with cardiovascular risk factors and without previous cardiovascular events undergoing immunotherapy was associated with a reduction in MACE and all-cause mortality without an increased risk of serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsImmune Checkpoint InhibitorsCardiovascular DiseasesCardiotoxicityHumansMaleFemaleAgedRetrospective StudiesMiddle AgedPropensity Score

Stichwörter der Autor:innen

Hydroxymethylglutaryl-CoA reductase inhibitorsImmune checkpoint inhibitorsMajor adverse cardiovascular eventsStatin

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Medicine, Danbury Hospital, Danbury, Connecticut, USA.
  • Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
  • Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.
  • Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Zitieren

APA

Song, J., Chi, K. Y., Jeon, H., Chang, Y. C., Xanthavanij, N., Tang, Z., Chang, Y., Chiang, C. H., Lin, Y. S., Lin, S., Xu, X. H., & Chiang, C. H. (2025). Statin and Immune-Related Cardiovascular Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology, 104(3), 319-326. https://doi.org/10.1159/000546204

Vancouver

Song J, Chi KY, Jeon H, Chang YC, Xanthavanij N, Tang Z, et al. Statin and Immune-Related Cardiovascular Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology. 2025;104(3):319-326. doi:10.1159/000546204

BibTeX
@article{Song2025,
  author = {Song, Junmin and Chi, Kuan-Yu and Jeon, Hyein and Chang, Yu-Cheng and Xanthavanij, Nutchapon and Tang, Zhiting and Chang, Yu and Chiang, Cho-Hung and Lin, Yu-Shiuan and Lin, Shuwen and Xu, Xiaocao Haze and Chiang, Cho-Han},
  title = {Statin and Immune-Related Cardiovascular Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors},
  journal = {Oncology},
  year = {2025},
  volume = {104},
  number = {3},
  pages = {319--326},
  doi = {10.1159/000546204}
}
Kostenlos starten →